|
Pancreatic carcinoma
|
|
0.720 |
GeneticVariation
|
BEFREE |
Long noncoding RNA LINC00673 has been widely explored for its role in the development and prognosis of many tumors, and 2 genome-wide association studies identified that LINC00673 rs11655237 was associated with susceptibility to pancreatic cancer.
|
30286619 |
2019 |
|
Pancreatic carcinoma
|
|
0.720 |
GeneticVariation
|
BEFREE |
<b>Background:</b> Two genome-wide association studies (GWASs) identified LINC00673 rs11655237 was associated with susceptibility to pancreatic cancer.
|
31118802 |
2019 |
|
Pancreatic carcinoma
|
|
0.720 |
GeneticVariation
|
GWASCAT |
Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer.
|
26098869 |
2015 |
|
Malignant Neoplasms
|
|
0.040 |
GeneticVariation
|
BEFREE |
Previous genome-wide association studies have identified that the LINC00673 rs11655237 C>T polymorphism is associated with the risk of several types of cancer.
|
31257678 |
2019 |
|
Malignant Neoplasms
|
|
0.040 |
GeneticVariation
|
BEFREE |
Expression of LINC00673 was significantly higher in adjacent normal tissues than in paired cancer tissues (<i>P</i><0.001) and significantly lower in the cancer or paired adjacent normal tissues of GC patients with rs11655237 allele A than in those with rs11655237 allele G (<i>P</i><0.001).
|
31118802 |
2019 |
|
Malignant Neoplasms
|
|
0.040 |
GeneticVariation
|
BEFREE |
Expression of LINC00673 was significantly higher in adjacent normal tissues than in paired cancer tissues ( P < .01) and significantly lower in the cancer or paired adjacent normal tissues of patients with cervical cancer having rs11655237 allele A than in those having rs11655237 allele G ( P < .001).
|
30286619 |
2019 |
|
Malignant Neoplasms
|
|
0.040 |
GeneticVariation
|
BEFREE |
Previous genome-wide association studies (GWASs) identified the <i>LINC00673</i> rs11655237 C>T polymorphism to be associated with the susceptibility of several malignant tumors.
|
29339420 |
2018 |
|
Primary malignant neoplasm
|
|
0.030 |
GeneticVariation
|
BEFREE |
Expression of LINC00673 was significantly higher in adjacent normal tissues than in paired cancer tissues (<i>P</i><0.001) and significantly lower in the cancer or paired adjacent normal tissues of GC patients with rs11655237 allele A than in those with rs11655237 allele G (<i>P</i><0.001).
|
31118802 |
2019 |
|
Primary malignant neoplasm
|
|
0.030 |
GeneticVariation
|
BEFREE |
Previous genome-wide association studies have identified that the LINC00673 rs11655237 C>T polymorphism is associated with the risk of several types of cancer.
|
31257678 |
2019 |
|
Primary malignant neoplasm
|
|
0.030 |
GeneticVariation
|
BEFREE |
Expression of LINC00673 was significantly higher in adjacent normal tissues than in paired cancer tissues ( P < .01) and significantly lower in the cancer or paired adjacent normal tissues of patients with cervical cancer having rs11655237 allele A than in those having rs11655237 allele G ( P < .001).
|
30286619 |
2019 |
|
Neoplasms
|
|
0.020 |
GeneticVariation
|
BEFREE |
Furthermore, stratified analysis indicated that rs11655237 T allele carriers in the following subgroups were more likely to develop HB: children older than 17 months, males, and those with tumors of clinical stages III + IV.
|
31178901 |
2019 |
|
Nephroblastoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
In conclusion, we failed to find any association between the LINC00673 rs11655237 C>T polymorphism and WT risk.
|
31257678 |
2019 |
|
Malignant neoplasm of pancreas
|
|
0.020 |
GeneticVariation
|
BEFREE |
<b>Background:</b> Two genome-wide association studies (GWASs) identified LINC00673 rs11655237 was associated with susceptibility to pancreatic cancer.
|
31118802 |
2019 |
|
Nephroblastoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
These data could be useful for reinforcing our understanding of the potential contribution of LINC00673 rs11655237 C>T to Wilms tumor susceptibility.
|
31657076 |
2019 |
|
Childhood Kidney Wilms Tumor
|
|
0.020 |
GeneticVariation
|
BEFREE |
These data could be useful for reinforcing our understanding of the potential contribution of LINC00673 rs11655237 C>T to Wilms tumor susceptibility.
|
31657076 |
2019 |
|
Childhood Kidney Wilms Tumor
|
|
0.020 |
GeneticVariation
|
BEFREE |
In conclusion, we failed to find any association between the LINC00673 rs11655237 C>T polymorphism and WT risk.
|
31257678 |
2019 |
|
Neuroblastoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
These findings add new evidence of the importance of <i>LINC00673</i> rs11655237 C>T to the risk of de</span>veloping neuroblastoma.
|
31005956 |
2019 |
|
Central neuroblastoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
These findings add new evidence of the importance of <i>LINC00673</i> rs11655237 C>T to the risk of de</span>veloping neuroblastoma.
|
31005956 |
2019 |
|
Malignant neoplasm of pancreas
|
|
0.020 |
GeneticVariation
|
BEFREE |
Long noncoding RNA LINC00673 has been widely explored for its role in the development and prognosis of many tumors, and 2 genome-wide association studies identified that LINC00673 rs11655237 was associated with susceptibility to pancreatic cancer.
|
30286619 |
2019 |
|
Childhood Neuroblastoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
These findings add new evidence of the importance of <i>LINC00673</i> rs11655237 C>T to the risk of de</span>veloping neuroblastoma.
|
31005956 |
2019 |
|
Childhood Neuroblastoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
Furthermore, stratified analysis indicated that the rs11655237 T allele carriers were associated with increas</span>ed neuroblastoma risk for patients with tumor originating from the adrenal gland (adjusted OR =1.51, 95% CI =1.06-2.14, <i>P</i>=0.021) and International Neuroblastoma Staging System (INSS) stage IV disease (adjusted OR =1.60, 95% CI =1.12-2.30, <i>P</i>=0.011).
|
29339420 |
2018 |
|
Neoplasms
|
|
0.020 |
GeneticVariation
|
BEFREE |
Furthermore, stratified analysis indicated that the rs11655237 T allele carriers were associated with increased neuroblastoma risk for patients with tumor originating from the adrenal gland (adjusted OR =1.51, 95% CI =1.06-2.14, <i>P</i>=0.021) and International Neuroblastoma Staging System (INSS) stage IV disease (adjusted OR =1.60, 95% CI =1.12-2.30, <i>P</i>=0.011).
|
29339420 |
2018 |
|
Central neuroblastoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
Furthermore, stratified analysis indicated that the rs11655237 T allele carriers were associated with increas</span>ed neuroblastoma risk for patients with tumor originating from the adrenal gland (adjusted OR =1.51, 95% CI =1.06-2.14, <i>P</i>=0.021) and International Neuroblastoma Staging System (INSS) stage IV disease (adjusted OR =1.60, 95% CI =1.12-2.30, <i>P</i>=0.011).
|
29339420 |
2018 |
|
Neuroblastoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
Furthermore, stratified analysis indicated that the rs11655237 T allele carriers were associated with increas</span>ed neuroblastoma risk for patients with tumor originating from the adrenal gland (adjusted OR =1.51, 95% CI =1.06-2.14, <i>P</i>=0.021) and International Neuroblastoma Staging System (INSS) stage IV disease (adjusted OR =1.60, 95% CI =1.12-2.30, <i>P</i>=0.011).
|
29339420 |
2018 |
|
Hepatoblastoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
In conclusion, we confirmed that the <i>LINC00673</i> rs11655237 C>T polymorphism may be associated with HB susceptibility.
|
31178901 |
2019 |